ANI Pharmaceuticals(ANIP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANIP ANI Pharmaceuticals

Trading 04-23 13:49:12 EDT

69.13

+0.18

+0.25%

High70.30	Low68.89	Vol77.93K
Open69.73	D1 Closing68.95	Amplitude2.04%
Mkt Cap1.49B	Tradable Cap1.16B	Total Shares21.59M
T/O5.43M	T/O Rate0.46%	Tradable Shares16.77M
P/B3.70	ROE-4.18%	EPS-1.04
52wk High70.48	52wk Low52.50	P/E-66.28
Dividend0.00	Div.Yield0.00	ROA0.84%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ANIP","market":"US","secType":"STK","nameCN":"ANI Pharmaceuticals","latestPrice":69.125,"timestamp":1745430490021,"preClose":68.95,"halted":0,"volume":77925,"delay":0,"floatShares":16768500,"shares":21585039,"eps":-1.042913,"marketStatus":"Trading","change":0.175,"latestTime":"04-23 13:49:12 EDT","open":69.73,"high":70.295,"low":68.89,"amount":5432755.668749999,"amplitude":0.020377,"askPrice":69.2,"askSize":35,"bidPrice":69.06,"bidSize":17,"shortable":3,"etf":0,"ttmEps":-1.042913,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1064980800000,"exchange":"NASDAQ","adjPreClose":68.95,"preHourTrading":{"tag":"盘前","latestPrice":69,"preClose":68.95,"latestTime":"08:45 EDT","volume":42,"amount":2898.32004,"timestamp":1745412313345},"postHourTrading":{"tag":"盘后","latestPrice":68.95,"preClose":68.95,"latestTime":"16:30 EDT","volume":5661,"amount":390325.95,"timestamp":1745353836837},"volumeRatio":0.467041,"impliedVol":0.4635,"impliedVolPercentile":0.644},"requestUrl":"/m/hq/s/ANIP/wiki","defaultTab":"wiki","newsList":[{"id":"2529950195","title":"5 Stocks With Recent Price Strength Amid Tariff-Led Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2529950195","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529950195?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 18:05","pubTimestamp":1745402700,"startTime":"0","endTime":"0","summary":"U.S. stock markets are witnessing extreme volatility in April due to the Trump administration’s tariffs on imported products from around the world. The baseline tariff of 10% was imposed on all imports on April 5.This seems to be the beginning of a global trade war. Economists and financial experts are highly concerned about the impact of these tariffs on U.S. economic growth, especially on inflation, which is already elevated and prolonged. Market participants fear a near-term recession and, in the worst-case scenario, a stagflation in the U.S. economy.Consequently, a handful of stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. Such stocks have a high chance of carrying the momentum forward.Five such stocks are — Heritage Insurance Holdings Inc. HRTG, Marex Group plc MRX, Kingstone Companies Inc. KINS, ANI Pharmaceuticals Inc. ANIP and HCI Group Inc. HCI.Heritage Insurance Holdings provides personal and commercial residential in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-stocks-recent-price-strength-100500170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCI","LU0566484027.USD","BK4127","ANIP","LU1559883803.SGD","KINS","HRTG","MRX","BK4007","BK4107"],"gpt_icon":0},{"id":"2529158505","title":"4 Stocks Trading Near 52-Week High With Room to Rise Further","url":"https://stock-news.laohu8.com/highlight/detail?id=2529158505","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529158505?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 20:22","pubTimestamp":1745324520,"startTime":"0","endTime":"0","summary":"Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived to be winners. However, stocks touching a new 52-week high are often predisposed to profit-taking, resulting in pullbacks and trend reversals.Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculations are not absolutely baseless, all stocks hitting a 52-week high are not necessarily overpriced.In fact, investors might lose out on top gainers in an attempt to avoid the steep prices.Stocks such as ANI Pharmaceuticals ANIP, Heritage Insurance HRTG, Avista AVA and Exelon EXC are expected to maintain their momentum and keep scaling new highs. Extensive information on a stock is necessary to understand whether or not there is scope for further upside.Here, we discuss a strategy to find the right stocks. The strategy borrows from the basics of momentum ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-stocks-trading-near-52-122200664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2346227817.USD","BK4606","LU0820561818.USD","BK4208","LU0820561909.HKD","EXC","BK4107","LU2362541513.USD","BK4081","LU1559883803.SGD","IE00BMQBXF63.USD","BK4585","LU0742534661.SGD","IE00BZ18W340.USD","LU2449327464.USD","HRTG","LU0820562030.AUD","LU2362541273.HKD","LU2362540622.SGD","LU0251142724.SGD","LU0943347566.SGD","LU1878469433.USD","IE00B3T34201.USD","LU1551013425.SGD","IE00BZ18W456.USD","ANIP","LU1551013342.USD","LU0689472784.USD","BK4588","BK4007","AVA","LU0566484027.USD"],"gpt_icon":0},{"id":"2529824463","title":"ANI Pharmaceuticals Is Maintained at Hold by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2529824463","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529824463?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 00:09","pubTimestamp":1745251740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 12:09 ET (16:09 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0566484027.USD","LU1559883803.SGD","ANIP"],"gpt_icon":0},{"id":"2529086508","title":"ANI Pharmaceuticals Inc : Truist Securities Raises Target Price to $65 From $62","url":"https://stock-news.laohu8.com/highlight/detail?id=2529086508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529086508?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 19:59","pubTimestamp":1745236793,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","ANIP","LU1559883803.SGD","BK4007"],"gpt_icon":0},{"id":"2529874832","title":"Truist Lifts Price Target on ANI Pharmaceuticals to $65 From $62, Keeps Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874832","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874832?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 18:55","pubTimestamp":1745232942,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals (ANIP) has an average rating of buy and mean price target of $81.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANIP"],"gpt_icon":0},{"id":"2528744487","title":"ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528744487","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528744487?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 21:15","pubTimestamp":1744895702,"startTime":"0","endTime":"0","summary":"Have you been paying attention to shares of ANI Pharmaceuticals ?Shares have been on the move with the stock up 6.7% over the past month. The stock hit a new 52-week high of $70.18 in the previous session. ANI Pharmaceuticals has gained 25.2% since the start of the year compared to the -5.4% move for the Zacks Medical sector and the -8.4% return for the Zacks Medical - Biomedical and Genetics industry.The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on February 28, 2025, ANI reported EPS of $1.63 versus consensus estimate of $1.44 while it beat the consensus revenue estimate by 8.98%.For the current fiscal year, ANI is expected to post earnings of $6.34 per share on $768.53 million in revenues. This represents a 21.92% change in EPS on a 25.09% change in revenues. For the next fiscal year, the company is expected to earn $7.11 per share on $829.44 million in rev","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-pharmaceuticals-inc-anip-soars-131502690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","LU1559883803.SGD","BK4007","ANIP"],"gpt_icon":0},{"id":"2527217592","title":"SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2527217592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527217592?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 19:32","pubTimestamp":1744803120,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy , a group of rare genetic disorders marked by progressive muscle weakness.Following positive FDA feedback, the company is advancing a fourth LGMD program to clinical development. Sarepta will soon start screening and dosing patients in the first-in-human clinical SRP-9005-101  study, to evaluate its investigational gene therapy SRP-9005 for LGMD type 2C/R5 .SRPT also announced completion of enrollment and dosing in the phase I proof-of-concept SRP-9004-102  study, which is evaluating SRP-9004 in patients with LGMD type 2D/R3 .The company also reiterated its plans to report data from the late-stage EMERGENE study, evaluating SRP-9003 in patients with LGMD type 2E/R4 , by first-half 2025. This study’s primary endpoint is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease. Following a pre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-provides-pipeline-updates-rare-113200363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002141913.USD","03165","ANIP","IE00BJJMRZ35.SGD","CTMX","IE0009355771.USD","RHHBY","LU1559883803.SGD","BK4007","SRPT","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0566484027.USD","BK4139","IE00BJT1NW94.SGD","BK4585"],"gpt_icon":0},{"id":"2527948964","title":"ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527948964","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527948964?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 17:10","pubTimestamp":1744708248,"startTime":"0","endTime":"0","summary":"Even during a down period for the markets, ANI Pharmaceuticals has gone against the grain, climbing to $68.06. Its shares have yielded a 16.1% return over the last six months, beating the S&P 500 by 23%. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.Is there a buying opportunity in ANI Pharmaceuticals, or does it present a risk to your portfolio?Dive into our full research report to see our analyst team’s opinion, it’s free.We’re glad investors have benefited from the price increase, but we don't have much confidence in ANI Pharmaceuticals. Here are three reasons why you should be careful with ANIP and a stock we'd rather own.With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals  develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-pharmaceuticals-anip-buy-sell-091048537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["POST","ANIP"],"gpt_icon":0},{"id":"2526181695","title":"ANI Pharmaceuticals Price Target Maintained With a $86.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2526181695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526181695?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 22:21","pubTimestamp":1744381260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANIP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 11, 2025 10:21 ET (14:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANIP"],"gpt_icon":0},{"id":"2526500796","title":"Guggenheim Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526500796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526500796?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 19:35","pubTimestamp":1744371328,"startTime":"0","endTime":"0","summary":"In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), with a price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-ani-pharmaceuticals-anip?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-ani-pharmaceuticals-anip?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANIP"],"gpt_icon":0},{"id":"2526543593","title":"Vaxcyte Stock Plummets 56% in a Month: Here's the Reason","url":"https://stock-news.laohu8.com/highlight/detail?id=2526543593","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526543593?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 01:07","pubTimestamp":1744304820,"startTime":"0","endTime":"0","summary":"Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases.In the past month, PCVX's shares have nosedived 56%. This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine  in healthy infants.Adding to this headwind, the broader biotech/drug sector is feeling the pressure from the resignation of a senior FDA official instrumental in driving biotech innovation, which has raised alarms around the agency’s ability to maintain momentum on innovation and regulatory clarity.Vaxcyte’s shares have plummeted more than 62% year to date compared with the industry’s 8% decline, as seen in the chart below. During this timeframe, the stock has also underperformed the broader Medical sector and the S&P 500 Index. The company’s shares are also trading below its 50 and 200-day moving averages.Vaxcyte intends to report full post-dose 4 booster data for VAX-24 by the end ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaxcyte-stock-plummets-56-month-170700030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456855351.SGD","LU0306807586.USD","LU1066051498.USD","LU0053671581.USD","LU0985481810.HKD","ETNB","SG9999011175.SGD","IE00BLSP4452.SGD","BK4585","BK4599","LU1057294990.SGD","SGXZ57979304.SGD","LU1559883803.SGD","LU1894683348.USD","BK4581","ANIP","BK4139","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","PCVX","BK4007","SG9999001176.SGD","LU0225284248.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","IE0002270589.USD","LU0225771236.USD","LU1066053197.SGD","LU0234572021.USD","IE0009354923.USD","LU0170899867.USD","LU0289739699.SGD","BK4568","LU1023059063.AUD","LU0122379950.USD","PFE","LU0566484027.USD","BK4592","SG9999002232.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2526131059","title":"BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2526131059","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526131059?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 01:44","pubTimestamp":1744220640,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo  plus Yervoy .The regulatory body approved Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients  with unresectable or metastatic microsatellite instability-high  or mismatch repair deficient  colorectal cancer .Please note that Opdivo , as a single agent or in combination with Yervoy, was previously granted accelerated approval in MSI-H/dMMR CRC in adult and pediatric patients  who have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.The latest FDA approval converts this second-line indication to full approval for Opdivo monotherapy and expands the indication for Opdivo plus Yervoy into the first-line setting.Shares of BMY have risen 7.9% in the past year against the industry’s decline of 20%.This randomized, multicenter, open-label study is evaluating Opdivo plus Yervoy compared to Opdivo alone or chemotherapy in patients with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmy-gets-fda-nod-label-174400443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1323610961.USD","LU0306806265.USD","LU1670711040.USD","CRC","LU0225771236.USD","ANIP","LU1670710661.SGD","LU2065171311.SGD","LU2360032135.SGD","BMY","IE00BFTCPJ56.SGD","BK4139","LU0321505868.SGD","LU1291159041.SGD","LU0061475181.USD","LU1559883803.SGD","LU0321505439.SGD","LU1989771016.USD","LU0096364046.USD","LU0266512127.USD","LU2125154935.USD","LU1093756168.USD","LU0868494617.USD","LU0456855351.SGD","LU0114720955.EUR","LU2125154778.USD","IE00BFXG1179.USD","LU2242652126.USD","LU0306807586.USD","LU0985481810.HKD","LU1718418525.SGD","BK4585","LU2065170008.USD","IE00BSNM7G36.USD","LU1032466523.USD","BK4532","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU1585245621.USD","LU1670711123.USD","BK4534","LU1868836757.USD","LU2065169927.USD","LU2065171402.SGD","FOLD","BK4559","LU1261432733.SGD","BK4588","IE0002141913.USD"],"gpt_icon":0},{"id":"2526315890","title":"Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526315890","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526315890?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 00:10","pubTimestamp":1744215012,"startTime":"0","endTime":"0","summary":"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report?ANI Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.When looking at the last two reports, this drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 18.07%, on average, in the last two quarters.For the most recent quarter, ANI was expected to post earnings of $1.44 per share, but it reported $1.63 per share instead, representing a surprise of 13.19%. For the previous quarter, the consensus estimate was $1.09 per share, while it actually produced $1.34 per share, a surprise of 22.94%.With this earnings history in mind, recent estimates have been moving higher for ANI. In fact, the Zacks Earnings ESP  for the company is positive, which is a great sign of an earnings beat, especially when you combine t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ani-anip-beat-estimates-again-161012933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP"],"gpt_icon":0},{"id":"2526512013","title":"Press Release: ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2526512013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526512013?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 18:50","pubTimestamp":1744195800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., April 09, 2025  -- ANI Pharmaceuticals, Inc.   today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open.Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:. A replay of the conference call will be available within two hours of the call's completion and will remain accessible for two weeks by dialing 800-753-8591 and entering access code 4921902.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","BK4585","ET","BK4590","LU1559883803.SGD","LU0566484027.USD","BK4007","BK4581","ANIP","BK4144","BK4588"],"gpt_icon":0},{"id":"2525437894","title":"VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2525437894","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525437894?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 18:55","pubTimestamp":1744109700,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals VRTX announced that the European Commission  has expanded the label of its blockbuster cystic fibrosis  drug, Kaftrio, to treat all patients aged two years and older who have at least one non-class I mutation in the CFTR gene.This approval was expected as the EMA’s Committee for Medicinal Products for Human Use  issued a positive opinion recommending Kaftrio’s approval in February for the above indication. With this expanded label, nearly 4,000 more CF patients living in the region are now eligible for treatment with the drug.Kaftrio is already approved for use in CF patients aged two years and older who have at least one F508del mutation in the CFTR gene.The drug is marketed by Vertex for similar indications in the United States under the trade name Trikafta.Year to date, shares of Vertex have gained 18% against the industry’s 7% decline.Estimates for 89bio’s loss per share have narrowed from $2.51 to $1.98 for 2025 in the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vrtx-secures-nod-expanded-cf-105500149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ETNB","LU0823416689.USD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","SG9999013999.USD","LU2237438978.USD","BK4567","IE00B894F039.SGD","BK4007","BK4023","BK4093","LU0320765992.SGD","BK4588","LU1585245621.USD","LU0757428866.USD","LU2362541273.HKD","LU2362540622.SGD","LU1559883803.SGD","BK4139","IE00BZ9MQY76.HKD","LU1093756168.USD","SG9999001176.SGD","IE0002270589.USD","VERX","BK4533","IE00BJT1NW94.SGD","IE00B19Z9P08.USD","LU1035775433.USD","BK4568","LU2236285917.USD","LU0109394709.USD","LU2324357040.USD","LU2462157665.USD","SGXZ57979304.SGD","CF","EC","LU2417539215.USD","SG9999001176.USD","VRTX","LU1430594728.SGD","ANIP","BK4551","LU0289739699.SGD","LU2456880835.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","BK4201"],"gpt_icon":1},{"id":"2525318890","title":"FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2525318890","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525318890?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 18:46","pubTimestamp":1744109160,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune diseases — systemic lupus erythematosus , idiopathic inflammatory myopathy  and diffuse systemic sclerosis .How Does the Fast Track Tag Benefit ALLO’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’。In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-three-fast-track-104600523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","IE00BFXG0V08.USD","IE00B5TLWC47.USD","ALLO","CTMX","FAST","BK4505","IIM","IE00BYQQ9H92.USD","ETNB","BK4104","BK4567","ANIP","SLE","BK4077","BK4139","BK4588"],"gpt_icon":0},{"id":"2525864720","title":"Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE","url":"https://stock-news.laohu8.com/highlight/detail?id=2525864720","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525864720?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 16:53","pubTimestamp":1744102380,"startTime":"0","endTime":"0","summary":"Chicago, IL – April 8, 2025 – Stocks in this week’s article are ANI Pharmaceuticals, Inc. ANIP, Expand Energy Corporation EXE, Avista Corp AVA and Contango ORE, Inc. CTGO.Play It Safe with 4 Low-Beta Stocks: ANIP, EXE, AVA, CTGO. President Donald Trump’s recently imposed tariff has rattled the equity market. The action will weigh on the already slowing domestic economy as the tariff will increase prices of both domestic and imported goods, thereby fueling uncertainty.Hence, stocks like ANI Pharmaceuticals, Inc., Expand Energy Corporation, Avista Corp and Contango ORE, Inc. are worth betting on.In the United States, Avista is among the leading utilities responsible for very low carbon emissions. To support its growing and large customer base, AVA has set up a solid capital investment program. From the estimated $525 million capital investment in 2025, AVA is planning to grow its investment to $650 million in 2029, securing a rate base growth of 5% to 6%. Notably, over the past 30 days, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-ani-085300951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1804176565.USD","EXEEL","EXEEW","LU2265009873.SGD","BK4007","BK4208","LU1878469433.USD","AVA","BK4213","EXE","EXEEZ","ANIP","CTGO","BK4168"],"gpt_icon":0},{"id":"2525041327","title":"Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO","url":"https://stock-news.laohu8.com/highlight/detail?id=2525041327","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525041327?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 20:23","pubTimestamp":1744028580,"startTime":"0","endTime":"0","summary":"President Donald Trump’s recently imposed tariff has rattled the equity market. The action will weigh on the already slowing domestic economy as the tariff will increase prices of both domestic and imported goods, thereby fueling uncertainty.In this context, creating a curated portfolio of low-beta stocks is a prudent strategy. This provides a safeguard against the uncertain market, equipping investors to navigate volatility with greater resilience and foresight.Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security’s price movement relative to the market. In this article, we are considering the S&P 500 as the market.If a stock has a beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tariff-woes-play-safe-4-122300709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4168","BK4208","BK4213","LU1804176565.USD","ANIP","EXE","BK4007","LU1878469433.USD","CTGO","LU2265009873.SGD","AVA"],"gpt_icon":0},{"id":"2524420475","title":"SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524420475","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524420475?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:29","pubTimestamp":1743766140,"startTime":"0","endTime":"0","summary":"Shares of Sarepta Therapeutics SRPT dropped more than 6% yesterday after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy . The therapy has been developed in collaboration with pharma giant Roche RHHBY.This hold has been placed in response to a patient’s death post-treatment with Elevidys, which was reported last month. Though the death was due to acute liver failure , Sarepta believes that the patient’s recent CMV infection might have contributed to the outcome. Investigation is still ongoing.In a letter to the World Duchenne Organization, Roche mentioned that the companies are pausing enrollment and dosing of study participants in three studies evaluating the therapy at the EU study sites. This hold will remain ‘until the analysis into the cause of death is complete.’。SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Sarepta retains the rights to market the gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-stock-down-ema-places-112900759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANIP","03165","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","RHHBY","SRPT","BK4585","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4007","CTMX","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2524260088","title":"BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524260088","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524260088?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 22:14","pubTimestamp":1743689640,"startTime":"0","endTime":"0","summary":"BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq  in adolescents aged 12-17 years with phenylketonuria .The study achieved its primary endpoint – patients treated with Palynziq achieved a statistically significant lowering in blood phenylalanine  levels compared to diet alone. The safety results were also consistent with the known profile of the drug.Palynziq is already approved in the United States to reduce blood Phe concentration in adults aged 18 years and older with PKU. The drug is currently the only enzyme therapy to treat the disease in this age group.PKU is a rare genetic disorder that prevents the body from breaking down Phe, an amino acid found in protein-rich foods, leading to toxic levels that can cause severe neurological damage. While newborn screening enables early diagnosis, lifelong dietary management is challenging, creating demand for innovative treatments like those developed by BioMarin.In the past 60 days, estimate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmrns-pku-drug-palynziq-meets-141400981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE0002270589.USD","CTMX","BK4585","BMRN","SSI","IE00B19Z3581.USD","ANIP","IE00B19Z3B42.SGD","BK4566","ETNB","IE00B7SZLL34.SGD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anipharmaceuticals.com","stockEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.073},{"period":"3month","weight":0.1855},{"period":"6month","weight":0.1631},{"period":"1year","weight":0.0507},{"period":"ytd","weight":0.2473}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.68,"avgChangeRate":0.064504},{"month":2,"riseRate":0.44,"avgChangeRate":0.015273},{"month":3,"riseRate":0.4,"avgChangeRate":-0.024868},{"month":4,"riseRate":0.56,"avgChangeRate":0.13359},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.019321},{"month":6,"riseRate":0.64,"avgChangeRate":0.036553},{"month":7,"riseRate":0.44,"avgChangeRate":-0.036667},{"month":8,"riseRate":0.44,"avgChangeRate":-0.010558},{"month":9,"riseRate":0.44,"avgChangeRate":0.023941},{"month":10,"riseRate":0.48,"avgChangeRate":-0.035044},{"month":11,"riseRate":0.6,"avgChangeRate":0.085385},{"month":12,"riseRate":0.44,"avgChangeRate":-0.053148}],"exchange":"NASDAQ","name":"ANI Pharmaceuticals","nameEN":"ANI Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ANI Pharmaceuticals(ANIP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ANI Pharmaceuticals(ANIP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ANI Pharmaceuticals,ANIP,ANI Pharmaceuticals股票,ANI Pharmaceuticals股票老虎,ANI Pharmaceuticals股票老虎国际,ANI Pharmaceuticals行情,ANI Pharmaceuticals股票行情,ANI Pharmaceuticals股价,ANI Pharmaceuticals股市,ANI Pharmaceuticals股票价格,ANI Pharmaceuticals股票交易,ANI Pharmaceuticals股票购买,ANI Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ANI Pharmaceuticals(ANIP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ANI Pharmaceuticals(ANIP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction